Diligence memo · auto-generated · as of July 2, 2026
Sprout Pharmaceuticals, Inc.
Sprout Pharmaceuticals, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Sprout Pharmaceuticals, Inc. operates in Pharmaceuticals, based in RALEIGH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sprout Pharmaceuticals, Inc. has raised $112M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $50M on 2015-05-22.
Most recent recorded round closed around 2015-05-22.
Valuation (modeled)modeled
Provath models Sprout Pharmaceuticals, Inc. at approximately $1.8B (range $162M–$4.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.85× the median modeled value of Series C Pharmaceuticals companies in 2013–2015 (19 peers) — value vs value, same stage and era. Within the normal band (85% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 6 months.
Last raise 11.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 11.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 92% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 93% of those peers.
Closest niche peers: Bellicum Pharmaceuticals, Inc, Paratek Pharmaceuticals Inc, Turing Pharmaceuticals AG, Seres Health, Inc., Syndax Pharmaceuticals Inc.
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.